Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIH phase I/II study of topical SXR1096 cream in Netherton syndrome
2023-507743-11-00Phase 2Completed
- Sponsor
- Sixera Pharma
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of SXR1096 in Netherton syndrome (NS) (2 arms), sponsored by Sixera Pharma. Primary endpoints: Safety and tolerability and Change in Investigator Global Assessment. Started Oct 2023; status: completed.
02
Drugs
SXR1096
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on 2023-507743-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507743-11-00.